Upper Extremity Deep Venous Thrombosis in Patients with 5-Fluorouracil-Containing Adjuvant Chemotherapy: Three Case Reports and a Review

Acta Oncologica

Volumn 43, Issue 1, 2004, Pages 108-112

  Tham, Josef ^a   Albertsson, Maria ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIMETABOLITE; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DALTEPARIN; FLUOROURACIL; FOLINIC ACID; MITOXANTRONE; OXALIPLATIN; TINZAPARIN;

ANTICOAGULANT THERAPY; ARM; ARM SWELLING; ARTERY SPASM; BOLUS INJECTION; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; CONTINUOUS INFUSION; CYSTECTOMY; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; HEMICOLECTOMY; HUMAN; INCIDENCE; INGUINAL HERNIA; INTERMETHOD COMPARISON; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK ASSESSMENT; SIGMOID; SYMPTOMATOLOGY; THROMBOGENICITY; THROMBOPHLEBITIS; VASCULAR ENDOTHELIUM; VASCULITIS;

ADULT; AGED; ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHLEBOGRAPHY; RISK ASSESSMENT; SAMPLING STUDIES; TREATMENT OUTCOME; UPPER EXTREMITY; VENOUS THROMBOSIS;

EID: 1442265880     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310021545     Document Type: Review

References (33)

1. Levine MN, Gent M, Hirsch J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
2. O'Neill VJ, Evans TRJ, Preson J, et al. A retrospective analysis of Hickman line-associated complications in patients with solid tumours undergoing infusional chemotherapy. Acta Oncol 1999; 38: 1103-7.
3. Barrios CH, Zuke JE, Blaes B, et al. Evaluation of an implantable venous access system in a general oncology population. Oncology 1992; 49: 474-8.
4. de Gregorio MA, Miguelena JM, Fernandez JA, et al. Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients. Eur Radiol 1996; 6: 748-52.
5. Kock HJ, Pietsch M, Krause U, et al. Implantable vascular access systems: experience in 1500 patients with totally implanted central venous port systems. World J Surg 1998; 22: 12-6.
6. Bonfils P, Luciani JA, Potard G, Bassot V. Prospective study of thromboses of the subclavian vein after setting implantable venous access systems in cervico-facial cancerology. Ann Otolaryngol Chir Cervicofac 1996; 113: 425-9.
7. Pucheu A, Dierhas M, Leduc B, et al. Fibrinolysis of deep venous thrombosis on implantable perfusion devices. Apropos of a consecutive series of 57 cases of thrombosis and 32 cases of fibrinolysis. Bull Cancer 1996; 83: 293-9.
8. Luciani A, Clement O, Halimi P, et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220: 655-60.
9. De Cicco M, Matovic M, Balestreri L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997; 86: 101-13.
10. Lyon RD, Griggs KA, Johnson AM, Olsen JR. Long-term follow-up of upper extremity implanted venous access devices in oncology patients. J Vasc Interv Radiol 1999; 10: 463-71.
11. Beheshti MV, Protzer WR, Tomlinson TL, et al. Long-term results of radiologic placement of a central vein access device. AJR Am J Roentgenol 1998; 170: 731-4.
12. Lersch C, Eckel F, Sader R, et al. Initial experience with Healthport miniMax and other peripheral arm ports in patients with advanced gastrointestinal malignancy. Oncology 1999; 57: 269-75.
13. Marie I, Levesque H, Cailleux N, et al. Deep venous thrombosis of the upper limbs. Apropos of 49 cases. Rev Med Interne 1998; 19: 399-408.
14. Bona RD, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997; 78: 137-40.
15. Durica SS. Venous thromboembolism in the cancer patient. Curr Opin Hematol 1997; 4: 306-11.
16. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-91.
17. Bona RD, Hickey AD, Wallace DM. Warfarin is safe as secondary prophylaxis in patients with cancer and a previous episode of venous thrombosis. Am J Clin Oncol 2000; 23: 71-3.
18. Balestreri L, De Cicco M, Matovic, et al. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 1995; 20: 108-11.
19. Monreal M, Davant E. Thrombotic complications of central venous catheters in cancer patients. Acta Haematol 2001; 106: 69-72.
20. Mughal MM. Complications of intravenous feeding catheters. Br J Surg 1989; 76: 15-21.
21. Monreal M, Lafoz E, Ruiz J, et al. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991; 99: 280-3.
22. Monreal M, Raventos A, Lerma R, et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines - a prospective study. Thromb Haemost 1994; 72: 548-50.
23. Hingorani A, Ascher E, Hanson J, et al. Upper extremity versus lower extremity deep venous thrombosis. Am J Surg 1997; 174: 214-7.
24. Hingorani A, Ascher E, Lorenson E, et al. Upper extremity deep venous thrombosis and its impact on morbidity and mortality rates in a hospital-based population. J Vasc Surg 1997; 26: 853-60.
25. Arenas-Marquez H, Anaya-Prado R, Barrera-Zepeda LM, et al. Complications of central venous catheters. Curr Opin Clin Nutr Metab Care 2001; 4: 197-200.
26. Bona RD. Thrombotic complications of venous catheters in cancer patients. Semin Thromb Hemost 1999; 25: 147-55.
27. Cwikiel M, Persson SU, Larsson H, et al. Changes of blood viscosity in patients treated with 5-fluorouracil - a link to cardiotoxicity? Acta Oncol 1995; 34: 83-5.
28. Cwikiel M, Zhang B, Eskilsson J, et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc 1995; 9: 561-6.
29. Cwikiel M, Eskilsson J, Wieslander JB, et al. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 1996; 10: 805-18; discussion 819.
30. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol 1996; 7: 731-7.
31. Bona RD. Thrombotic complications of venous catheters in cancer patients. Semin Thromb Hemost 1999; 25: 147-55.
32. Kinhult S, Albertsson M, Eskilssson J, Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning 2001; 23: 1-8.
33. Pectasides D, Tsavdaridis D, Aggouriaki C, et al. Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients. Anticancer Res 1999; 19: 3521-6.